Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cyclerion Therapeutics In...

    NASDAQ: CYCN · Real-Time Price · USD
    3.08
    -0.09 (-2.84%)
    At close: Jun 06, 2025, 10:01 AM

    Cyclerion Therapeutics Statistics

    Share Statistics

    Cyclerion Therapeutics has 3.21M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 3.21M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 0.02%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1,792

    FTD / Avg. Volume

    n/a
    		 8.8%

    Short Selling Information

    The latest short interest is 25.09K, so 0.82% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 25.09K

    Short % of Shares Out

    n/a
    		 0.82%

    Short % of Float

    n/a
    		 1.03%

    Short Ratio (days to cover)

    n/a
    		 1.56

    Valuation Ratios

    The PE ratio is -2.65 and the forward PE ratio is -0.15. Cyclerion Therapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -2.65

    Forward PE

    n/a
    		 -0.15

    PS Ratio

    n/a
    		 4.05

    Forward PS

    n/a
    		 0.1

    PB Ratio

    n/a
    		 0.92

    P/FCF Ratio

    n/a
    		 -1.87

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Cyclerion Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 5.83

    Quick Ratio

    n/a
    		 5.83

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $2,000,000

    Profits Per Employee

    n/a
    		 $-3,057,000

    Employee Count

    n/a
    		 1

    Asset Turnover

    n/a
    		 0.21

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 19.62% in the last 52 weeks. The beta is 1.55, so Cyclerion Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.55

    52-Week Price Change

    n/a
    		 19.62%

    50-Day Moving Average

    n/a
    		 2.94

    200-Day Moving Average

    n/a
    		 2.89

    Relative Strength Index (RSI)

    n/a
    		 53.64

    Average Volume (20 Days)

    n/a
    		 20,373

    Income Statement

    In the last 12 months, Cyclerion Therapeutics had revenue of 2M and earned -3.06M in profits. Earnings per share was -1.21.

    Revenue

    n/a
    		 2M

    Gross Profit

    n/a
    		 2M

    Operating Income

    n/a
    		 -3.63M

    Net Income

    n/a
    		 -3.06M

    EBITDA

    n/a
    		 -3.63M

    EBIT

    n/a
    		 -3.63M

    Earnings Per Share (EPS)

    n/a
    		 -1.21
    Full Income Statement

    Balance Sheet

    The company has 3.23M in cash and 0 in debt, giving a net cash position of 3.23M.

    Cash & Cash Equivalents

    n/a
    		 3.23M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -267.49M

    Total Assets

    n/a
    		 9.85M

    Working Capital

    n/a
    		 3.43M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -4.33M and capital expenditures 0, giving a free cash flow of -4.33M.

    Operating Cash Flow

    n/a
    		 -4.33M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -4.33M

    FCF Per Share

    n/a
    		 -1.72
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -181.4% and -152.85%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -181.4%

    Pretax Margin

    n/a
    		 -152.85%

    Profit Margin

    n/a
    		 -152.85%

    EBITDA Margin

    n/a
    		 -181.4%

    EBIT Margin

    n/a
    		 -181.4%

    FCF Margin

    n/a
    		 -216.65%

    Dividends & Yields

    CYCN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for CYCN.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 16, 2023. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 May 16, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -33.8

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist